ClinicalTrials.gov
ClinicalTrials.gov Menu

TCUPS- Tolvaptan Use in Cyctinuria and Urolithiasis: A Pilot Study (TCUPS)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT02538016
Recruitment Status : Recruiting
First Posted : September 2, 2015
Last Update Posted : October 1, 2018
Sponsor:
Collaborator:
Otsuka America Pharmaceutical
Information provided by (Responsible Party):
Caleb Nelson, Boston Children’s Hospital

Study Description
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information
Brief Summary:
The goal of this research project is to establish that in short-term use, tolvaptan is a safe and potentially effective new therapy for cystinuria, by conducting a short-term pilot study of the safety and tolerability of this drug, and assess impact on urinary stone risk parameters, among adolescent and young adult patients with clinical cystinuria.

Condition or disease Intervention/treatment Phase
Cystinuria Drug: Tolvaptan Not Applicable

Study Design
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 8 participants
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Use of Tolvaptan, a Vasopressin Antagonist, to Increase Urine Dilution and Reduce Cystine Urolithiasis Among Patients With Homozygous Cystinuria: a Pilot Investigation
Study Start Date : October 2016
Estimated Primary Completion Date : December 2018
Estimated Study Completion Date : December 2019

Resource links provided by the National Library of Medicine

Drug Information available for: Tolvaptan

Arms and Interventions
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Arm Intervention/treatment
Tolvaptan Drug: Tolvaptan


Outcome Measures
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Primary Outcome Measures :
  1. The short-term safety profile of tolvaptan therapy in adolescent patients with cystinuria will be measured by daily hospital visits where they will be monitored for alterations in blood pressure. [ Time Frame: 2 years ]
  2. The short-term safety profile of tolvaptan therapy in adolescent patients with cystinuria will be measured by daily blood tests. [ Time Frame: 2 years ]

Secondary Outcome Measures :
  1. The short-term effect of tolvaptan on urinary risk factors for urolithiasis in adolescent patients with cystinuria will be measured by daily composite urine analysis. [ Time Frame: 2 years ]

Eligibility Criteria
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   12 Years to 29 Years   (Child, Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Males and females age 12 - 29 years
  • Weight ≥ 25kg (55 lbs)
  • Confirmed cystinuria diagnosis
  • Specific blood test levels (done within the past 6 months)

Exclusion Criteria:

  • Concurrent non-renal disease that might increase risk of complications due to aquaresis
  • Liver or biliary disease (chronic or acute)
  • Malabsorption syndrome or other gastrointestinal condition that may interfere with response to therapy
  • Non-cutaneous malignancy within last 5 years
  • History of adverse reaction or allergy to Tolvaptan or other arginine vasopressin V2-receptor antagonists
Contacts and Locations
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02538016


Contacts
Contact: Alyssia Venna, MBS 617-919-6352 alyssia.venna@childrens.harvard.edu

Locations
United States, Massachusetts
Boston Children's Hospital Recruiting
Boston, Massachusetts, United States, 02115
Contact: Alyssia Venna, MBS    617-919-6352    alyssia.venna@childrens.harvard.edu   
Principal Investigator: Caleb P Nelson, MD, MPH         
Sponsors and Collaborators
Caleb Nelson
Otsuka America Pharmaceutical
Investigators
Principal Investigator: Caleb Nelson, MD, MPH Boston Children’s Hospital
More Information
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Responsible Party: Caleb Nelson, MD, MPH, Boston Children’s Hospital
ClinicalTrials.gov Identifier: NCT02538016     History of Changes
Other Study ID Numbers: 16726
First Posted: September 2, 2015    Key Record Dates
Last Update Posted: October 1, 2018
Last Verified: September 2018

Keywords provided by Caleb Nelson, Boston Children’s Hospital:
Cystinuria
Kidney Stones

Additional relevant MeSH terms:
Urolithiasis
Cystinuria
Urologic Diseases
Renal Aminoacidurias
Renal Tubular Transport, Inborn Errors
Kidney Diseases
Metabolism, Inborn Errors
 Genetic Diseases, Inborn
Metabolic Diseases
Tolvaptan
Antidiuretic Hormone Receptor Antagonists
Molecular Mechanisms of Pharmacological Action
Natriuretic Agents
Physiological Effects of Drugs